Entasis Therapeutics Holdings Inc. announced the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19th 2021. Ms. Triola will be responsible for global commercial strategy, including U.S. sales and marketing operations. Ms. Triola brings over 20 years of experience in the launch and commercialization of products across multiple therapeutic areas and diverse settings of care, including the hospital and community. She previously served as the Vice President, Marketing at Summit Therapeutics where she was instrumental in developing the commercial strategy for the company’s first product against C. difficile infections. Prior to joining Summit, Ms. Triola held commercial leadership roles at Flexion Therapeutics, Chiasma, Cubist, and Biogen.